Cancer & SURVIVEiT News

The SURVIVEiT® NewsRoom provides patients with quick access to exclusive news, treatment breakthroughs, survivor stories, and expert interviews providing the latest insight about this rapidly evolving industry. Visit our NewsRoom often and follow us on Facebook.

Blog_Header_Template_-_Navigating_Now_peace_of_mind_in_cancer

Navigating The Elusive ‘Peace of Mind’ in Cancer | Navigating Now

What I want to bring to light this month can be an extremely difficult subject. So difficult in fact, that many shy away from it. The topic of second opinions...
A Cancer Patient’s Guide To Getting A Remote Second Opinion

A Cancer Patient’s Guide To Getting A Remote Second Opinion

With the rapid advancements in what we’re learning about cancer, and how it’s being treated, it’s common for patients and their caregivers to feel unsure, afraid and helpless after a...
FDA_Drug_Newsroom

FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma

FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma On June 22, 2020, the Food and Drug Administration granted accelerated approval to selinexor (XPOVIO, Karyopharm Therapeutics) for adult patients with...
SURVIVEiT_Immunotherapy_Cancer_Patient_Story__Keeping_a_Positive_Outlook_When_Melanoma_Returned

Immunotherapy Cancer Patient Story: Keeping a Positive Outlook When Melanoma Returned

During Cancer Immunotherapy Awareness Month, we want to share cancer patient stories and how they came to find immunotherapy as a treatment option. See how Summer's positive outlook and support...
FDA granted accelerated approval to tazemetostat for follicular lymphoma

FDA granted accelerated approval to tazemetostat for follicular lymphoma

FDA granted accelerated approval to tazemetostat for follicular lymphoma On June 18, 2020, the Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK, Epizyme, Inc.), an EZH2 inhibitor, for...
FDA_Drug_Newsroom

FDA approves pembrolizumab for adults and children with TMB-H solid tumors

FDA approves pembrolizumab for adults and children with TMB-H solid tumors On June 16, 2020, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co., Inc.)...
FDA_Drug_Newsroom

FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer

FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer On June 15, 2020, the Food and Drug Administration granted accelerated approval to lurbinectedin(ZEPZELCA, Pharma Mar S.A.) for...
FDA_Drug_Newsroom

FDA approves gemtuzumab ozogamicin for CD33-positive AML in pediatric patients

FDA approves gemtuzumab ozogamicin for CD33-positive AML in pediatric patients On June 16, 2020, the Food and Drug Administration extended the indication of gemtuzumab ozogamicin (MYLOTARG, Wyeth Pharmaceuticals LLC) for...
SURVIVEiT_Cancer_Survivor_QA___What’s_The_First_Thing_To_Do_After_A_Cancer_Diagnosis_

Cancer Survivor Q&A | What’s The First Thing To Do After A Cancer Diagnosis?

SURVIVEiT®’s Survivor Advisory Council & Committee is made up of cancer survivors who have travelled the path and understand the journey in a way others cannot. Their wisdom is what...
SURVIVEiT_A_Cancer_Patient’s_Experience_With_Immunotherapy

A Cancer Patient’s Experience With Immunotherapy

After a cancer diagnosis, it’s important that you gather as much information as you can so you can truly advocate for yourself. This includes understanding your specific type of cancer...
FDA_Drug_Newsroom

FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC

FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC On May 29, 2020, the Food and Drug Administration approved ramucirumab (CYRAMZA, Eli Lilly and Company) in combination with erlotinib for...
FDA_Drug_Newsroom

FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC

FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC On May 26, 2020, the Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb...